Search This Blog

Tuesday, May 21, 2024

Alvotech, Dr. Reddy’s to Commercialize Biosimilar Candidate to Prolia® & Xgeva® in U.S., Europe and UK

 

  • Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
  • Alvotech will be responsible for development and manufacture of the product
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)